Enanta’s diversified portfolio is focused on products for HCV and a pipeline focused primarily on unmet medical needs such as non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV)

Latest News